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Abstract
This article summarises the information that should be provided to women and referring physicians about breast ultrasound (US).
After explaining the physical principles, technical procedure and safety of US, information is given about its ability to make a
correct diagnosis, depending on the setting in which it is applied. The following definite indications for breast US in female subjects
are proposed: palpable lump; axillary adenopathy; first diagnostic approach for clinical abnormalities under 40 and in pregnant or
lactating women; suspicious abnormalities at mammography or magnetic resonance imaging (MRI); suspicious nipple discharge;
recent nipple inversion; skin retraction; breast inflammation; abnormalities in the area of the surgical scar after breast conserving
surgery or mastectomy; abnormalities in the presence of breast implants; screening high-risk women, especially when MRI is not
performed; loco-regional staging of a known breast cancer, when MRI is not performed; guidance for percutaneous interventions
(needle biopsy, pre-surgical localisation, fluid collection drainage); monitoring patients with breast cancer receiving neo-adjuvant
therapy, whenMRI is not performed.Possible indications such as supplemental screening after mammography for women aged 40–
74 with dense breasts are also listed. Moreover, inappropriate indications include screening for breast cancer as a stand-alone
alternative to mammography. The structure and organisation of the breast US report and of classification systems such as the BI-
RADS and consequent management recommendations are illustrated. Information about additional or newUS technologies (colour-
Doppler, elastography, and automated whole breast US) is also provided. Finally, five frequently asked questions are answered.
Teaching Points
• US is an established tool for suspected cancers at all ages and also the method of choice under 40.
• For US-visible suspicious lesions, US-guided biopsy is preferred, even for palpable findings.
• High-risk women can be screened with US, especially when MRI cannot be performed.
• Supplemental US increases cancer detection but also false positives, biopsy rate and follow-up exams.
• Breast US is inappropriate as a stand-alone screening method.
Keywords Breast cancer . Breast ultrasound (US) . BI-RADS . Colour-Doppler . Elastography . Automated whole breast
ultrasound
Introduction
Breast ultrasound (US) is one of the four main methods
for diagnosing breast diseases, together with mammogra-
phy, magnetic resonance imaging (MRI), and image-
guided needle biopsy.
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This article is the third in a series of recommendations for
information for women issued by the European Society of
Breast Imaging (EUSOBI), the first focusing on mammogra-
phy [1, 2] and the second on breast MRI [3]. It is addressed to
the women themselves and to physicians dealing with patients
for whom breast US is, or may be, under consideration. In
particular, seven special information notes (from A to G)
and five frequently asked questions are formulated for use in
direct communication with women. Considering the relevant
differences across European countries in terms of available
technology, national guidelines, clinical practices, health care
systems, and insurance coverage, these recommendations can
have different applications under local conditions.
A search on the PubMed/Medline has been performed for
papers published from January 2007 to December 2016, sub-
sequently updated to December 2017, using the terms “breast”
AND “ultrasound”. Articles with an informative content most
suitable for the aim of the article were selected as references
with special regard to predetermined issues: safety/quality;
protocols and techniques; test performance (sensitivity and
specificity); screening and clinical indications. Other articles
were added as references as suggested by the authors.
The entire text underwent a double evaluation by the au-
thors, each of them contributing with relevant intellectual con-
tent. However, as many different issues are considered, single
authors generally agreeing on these recommendations may
have different opinions on individual statements.
General issues, safety, and quality
Ultrasound is an imaging method based on the application of
sound waves, i.e. not radiation but mechanical periodic
compression/rarefaction waves of a medium, for producing
images of the internal body structures. In particular, this meth-
od uses sound waves with frequencies above the upper limit of
human hearing (limited from 16 Hz to 20 kHz), indeed de-
fined as ultrasound, in particular frequencies of at least
1 MHz, able to penetrate biologic tissues. Images are obtained
by sending pulses of US waves into the tissues using a probe,
which is a transducer that can transmit and receive US. Gel,
which is used as a propagation medium, is interposed between
the US probe and the skin of the region to be examined. These
waves are variably reflected as echoes by the tissues, from
which comes the denomination of echography, other equiva-
lent denominations being sonography or ultrasonography.
Reflected echoes are received by the probe and forwarded as
electronic signals to a computer system that finally generates
the images [4, 5].
Importantly, US is a technique that does not expose the
woman to radiation and its related risks. The US waves used
for medical imaging do not cause injury to human tissues,
allowing a very safe diagnostic approach [4–6]. There are no
contraindications to breast US. Practical difficulties can be
encountered in women with severe disabilities preventing
the correct positioning or in obese women due to limited pen-
etration depth. The cost of breast US is comparable to that of
mammography and much lower than that of breast MRI, al-
though the time spent by the physician performing the exam-
ination is usually not (or only scarcely) included in the reim-
bursement evaluation.
Assurance of the technical quality of US equipment should
follow specific protocols [7, 8]. As a general suggestion,
women should be aware thatUS equipment older than 10 years
may not yield state-of-the-art examination results [8, 9].
When using the most common modality of US image gen-
eration (i.e. with the probe manually moved on the body sur-
face of a patient — handheld, also called manual, US), the
diagnostic performance of breast US is dramatically influ-
enced by the specific competence and experience of the oper-
ator. As a consequence, handheld US of the breast should only
be carried out by specially trained and experienced physi-
cians, preferentially a breast radiologist. In fact, in the vast
majority of European countries, handheld breast US is per-
formed by physicians, not by radiographers or so-called
“sonographers”. Of note, although automated three-
dimensional whole-breast US systems can be used by
radiographers for generating three-dimensional US datasets
[10], the interpretation of the images always requires the ex-
perience of an expert in handheld breast US to keep false
positive and false negative calls as low as possible [11]. In
the case of suspicious findings with automated breast US,
handheld US should be performed to confirm the finding
and make a clinical decision [12, 13].
During handheld breast US, the physician chooses images
to capture and makes them available with the report. In fact,
unlike other breast imaging methods such as mammography
or MRI, the vast majority of the handheld US examination is
not recorded. Of note, many experienced breast radiologists
use breast US for targeted investigations of areas of concern,
documenting abnormalities that she/he has noticed during the
scanning process. When a whole breast handheld examination
is performed, at least one image of normal findings for each
quadrant and for the retroareolar region, optionally for the
axilla, should be documented. Notably, if an examiner over-
looks an abnormality during the US examination, that abnor-
mality will not be available for later reviews of that US exam-
ination. This, in turn, means that quality assurance for hand-
held breast US is more challenging than it is for other breast
imaging methods, due to a higher proportion of human vari-
ability in determining the diagnostic result: handheld breast
US is highly operator-dependent. Third parties cannot review
a previous study with the only exception of those findings
identified and documented with images by the original exam-
iner. However, this is not true for automated whole breast US,
a standardised approach, where the whole examination is
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recorded, even though this technique suffers from other spe-
cific limitations (see below).
A breast radiologist can compare US findings with those
from mammography and MRI, integrate clinical information,
appropriately define further work-up in terms of time-interval
and imaging modalities to be used and, when indicated, per-
form an imaging-guided percutaneous biopsy. EUSOBI
strongly encourages women to ask for a dedicated breast ra-
diologist to perform their breast US.
Note A. The high operator-dependence of hand-held
breast US implies that the specific experience and exper-
tise of the examiner strongly determines the reliability of
the results. This means that breast radiologists are the
most suitable professionals for performing handheld
breast US. In fact, they are able to check for appropri-
ateness of the breast US examination, to provide correla-
tion with other breast imaging studies already performed
(mammography or MRI), to propose and perform further
imaging work-up or needle biopsy, and to define the cor-
rect interval time to the next follow-up breast imaging
study. Breast US is one of the cases where the expertise
of the examiner is of greater importance than the quality
of the technical equipment. Notably, guidelines suggest,
as a general rule, that equipment older than 10 years
should be replaced [9]. Thus, ask for a breast radiologist
to perform your breast US and ask for dedicated, not
outdated, US equipment.
Examination protocol and technical issues
Clear instructions and explanations regarding the entire pro-
cedure should be provided to the woman. The optimal proto-
col for performing breast US requires the patient to lie in the
supine position with the chest undressed and with arms flexed
behind the head to flatten the breast or in the oblique position
for scanning the lateral part of the breast and, when needed,
axilla [13]. Breast US can even be performed in women who
cannot lie down or flex the arms behind the head, although in
these conditions it becomes more difficult to perform the ex-
amination and the results might be suboptimal.
A clinical US scanner with dedicated linear probes working
from 10 to 15–18 MHz for the superficial details or small
breasts, and from 4 to 8 MHz for deeper areas or very large
breasts, should be employed. A contact gel is always applied
to the breast to allow the US waves to be sent from the probe
to the breast tissues. The probe is placed on the breast and
moved in multiple directions, with a gentle pressure that
makes US usually painless and well tolerated.
Importantly, for many indications, breast US is aimed at
evaluating specific clinical findings or findings detected
through other imaging modalities. In many cases, only a uni-
lateral, targeted breast US examination is performed and not a
bilateral whole breast US. Thus, whether both breasts, only
one breast or just a part of one breast will be scanned depends
on the indication, mammographic breast density, and local
policies. The axilla will be scanned in women with clinical
or radiological abnormalities, in women with personal history
of breast cancer, and whenever the radiologist evaluates this to
be useful. Of note, routine axillary scanning during screening
breast US after negative mammography showed no effect on
additional cancer detection but increased the number of false-
positive results [14]. If suspicious nodes are seen in the axilla,
other nearby lymph node stations (i.e. supra- or infra-
clavicular locations, in the neck or below the clavicle) may
be examined.
Note B. Follow carefully the instructions of the radiolo-
gists during the breast US examination. She/he will ask
you to move your trunk or your arms to get the best
position for scanning each of your breasts. Your cooper-
ation is needed to get the best diagnostic performance
and reduce the examination time. A certain pressure of
the probe on your breast is necessary to avoid artefacts,
i.e. unwanted alterations of the images possibly reducing
the diagnostic power of the examination. If the pressure is
uncomfortable, please tell the examiner immediately.
Additional US techniques
Both colour-Doppler and elastography are special tools that
may be available on US machines. Nowadays, almost all US
equipment provide colour-Doppler images. Elastography is
much less widespread and currently used only in some centers
for particular cases.
Colour-Doppler exploits the Doppler effect, a physical
phenomenon according to which the frequency or wavelength
of a wave changes for an observer who is moving relative to
the wave source or vice versa. A common example is the
change of pitch heard when a vehicle sounding a siren ap-
proaches, passes, and recedes. Colour-Doppler representation
of the vessels, obtained using no or minimal pressure to pre-
vent vessels from collapsing [15], are usually superimposed
on standard grey-scale US images (duplex modality). This
approach allows for identifying vessels in the context of breast
tissue, in particular around and inside mass lesions. The pres-
ence of vessels can be an additional criterion aiding the dif-
ferentiation of malignant from benign lesions, but is not suf-
ficient alone to characterise a lesion [13, 16]. Moreover, when
performing a US-guided biopsy, colour-Doppler can be useful
to visualise the course of the vessels in order to avoid crossing
them with the needle, causing haematoma [17].
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Elastographymeasures tissue stiffness looking at modifica-
tions of the US image of a given lesion after applying a me-
chanical stress [18]. The stress is mostly applied as a manual
pressure, requiring a very gentle quavering of the probe (not
causing any discomfort) or using ultrasound waves as a source
of mechanical stress (shear wave elastography) [19]. The pre-
mise for interpreting the results of this tool is that malignant
tissues are mostly, but not always stiffer than benign tissues.
Colour-coded maps are provided for visual representation of
the results. When using the shear wave technique, a lesion
stiffness quantification is given (in kilopascal, kPa, or in m/s).
Using this approach, a significant increase in specificity has
been reported [20]. Elastography evaluation of breast lesions
has been recently included as an associated feature in the BI-
RADS system [21] (see below for BI-RADS categories).
Both colour-Doppler and elastography are, however, not
mandatory elements of a breast US examination. Other com-
plementary ultrasound techniques, such as harmonic imaging
and compound US imaging may be associated to grey-scale
images.
Automated whole breast US
Automated whole breast US, approved by the Food and Drug
Administration in 2009, offers the potential for acquiring a
volumetric three-dimensional breast dataset with a standardise
examination protocol [22, 23]. It can be performed by a radi-
ographer/technician, with a total time for patient preparation
and acquisition ranging approximately between 10 and 15min
[10]. A longer time is needed when multiple acquisitions have
to be performed in large breasts. As explained above, auto-
mated image acquisition still implies interpretation and
reporting by an expert in handheld breast US at a later time.
If findings warrant further assessment, the woman needs to be
recalled for a handheld US. The main advantage of automated
breast US is a reduced operator dependence, resulting in a
higher reproducibility of the examination. The main disadvan-
tages are the need of recall in the case of positive examination
a number of additional false positive findings, with an increase
of the recall rate of 28.5 per 100 screened women [23]. The
possibility of using this technique as an additional tool for
screening women with dense breasts without other risk factors
has been explored, with a cancer detection rate additional to
mammography up to 2.4 per 1000 women screened [24].
More well-designed large studies are welcome.
As automated breast US is still not widely used, in this
article when the term breast US is used without specifications,
we mean handheld breast US.
Note C. The experience with automated breast US is
promising but still relatively limited. If the woman is ex-
amined with this technique, it’s important to remember
that the report is the result of an evaluation performed
by a radiologist in a separate session and that, if a sus-
picious finding is detected, the woman has to be recalled
and a work-up with targeted handheld US is necessary.
After the procedure
When the examination is completed, the woman is provided
with a paper or tissue towel for removing the residual gel. She
can get dressed again and goes home. The report is usually
generated at the end of the examination. When correlation
with a complex clinical history and/or other imaging modali-
ties is needed, the report may need more time to be generated.
In the majority of cases, the breast radiologist will talk directly
to the woman immediately after the end of the examination.
The time for report availability can vary across countries and
centres. For the case of automated breast US, see above the
Note C.
Test performance
Performance refers to the general ability of a test, here breast
US, to make a correct diagnosis, i.e. to see cancers when they
are present (sensitivity) or to exclude them when they are not
(specificity).
No test is perfect. This is also true for breast US [6, 25–27].
Its sensitivity and specificity also depend on the specific set-
ting (i.e. the indication) in which it is applied, particularly in
the major distinction between its application in symptomatic
women (diagnostic performance) or in asymptomatic women
(screening performance).
Considering the high operator-dependence, and the fact
that most US studies are performed together with, and com-
plementary to, other examinations (clinical examination and
mammography), it is difficult to define precisely a sensitivity
for US alone. It varies strongly depending on lesion size, type
of breast tissue and (as for all methods) on patient selection.
When a woman has focal symptoms, typically a palpable
lump, US is performed as a targeted examination and has a
high sensitivity [6]. In this clinical setting, US is useful for
differentiating liquid benign lesions (cysts) from solid masses,
characterising solid masses, and deciding whether a US-
guided needle biopsy should be performed [21]. Since the
negative predictive value (NPV) of breast US, i.e. the proba-
bility that a negative examination is truly negative (no cancers
are present) is usually not perfect (like that of mammography),
exclusion of malignancy can require a combined evaluation of
ultrasound with mammography and clinical findings. Based
on US, it is possible to exclude malignancy in case of patho-
gnomonic findings like simple cysts or when a low suspicion
finding (like some mammographic asymmetry) correlates at
US with homogeneously hyperechoic normal gland tissue or
452 Insights Imaging (2018) 9:449–461
with a mobile and elastic well-circumscribed oval mass com-
patible with a fibroadenoma. The addition of mammography
to US should be considered whenever the pre-test probability
of malignancy is high enough, usually in women over 40 or in
women with somewhat atypical US findings.
Sensitivity of breast US is high for characterising mammo-
graphic masses, lower in in the presence of isolated calcifica-
tions, i.e. of those without an associated mass. If the suspicion
of cancer persists after targeted US or the lesion cannot be
clearly identified at US, further work-up is necessary such as
a needle biopsy under mammographic guidance or, in partic-
ular cases, contrast-enhanced MRI or contrast-enhanced
mammography.
In women with dense breasts, US screening is able to detect
additional cancers, described to be from 2 to 7 every 1000
negative mammograms [27, 28], to be considered as the com-
bined result of the limitations of mammography in the pres-
ence of dense breasts and of other associated risk factors. High
rates (over 2 per 1000 mammograms) of additional cancer
detection rate may be due to population preselection. The
masking effect of breast density appears to be lower for US
than for mammography. In general, the sensitivity of US is
good, even for small cancers that occur in dense (usually
hyperechoic) surrounding tissue and present as masses, with
or without microcalcifications. The sensitivity decreases for
masses in large breasts, in fatty breasts, and in breasts with
inhomogeneous breast tissue, either by many interposed fatty
components or due to mastopathy changes, being strongly
variable with lesion size, palpability, composition of the sur-
rounding tissue, and breast size.
Notably, breast US also detects a variety of non-palpable
benign lesions, which are very common in the breast but may
otherwise have gone unnoticed, sometimes requiring needle
biopsy, showing their benignancy (false positives). This is one
of the major drawbacks of the use of breast US as a screening
tool. A systematic review of supplemental screening in wom-
en with dense breasts reported very low positive predictive
value of both handheld and automated breast US (from 3.2
to 7.5%) and a biopsy rate as high as about 6% [29].
Invasive cancers not visible or not detected on US are
in general either very small, behind the nipple or lesions
which are difficult to distinguish from normal gland or fat
tissue or from fibrocystic changes, such as invasive lobular
cancers, accounting for up to 15% of all breast cancers
[30]. US may also miss microinvasive cancers and diffuse-
ly growing cancers. Accordingly, suspicious findings at
clinical examination, mammography, or MRI should not
be dismissed because of a normal US, even when US
has been targeted to the region thought to harbour the
finding. Moreover, US is less sensitive than mammogra-
phy for non-invasive breast cancers (ductal carcinoma in
situ, DCIS) commonly detected at mammography due to
the presence of calcifications [31].
Note D. When both mammography and breast US are
requested, US should be performed after mammography.
The best scenario is that both mammography and US are
evaluated at the same time from the same radiologist
providing a unique conclusion from the two examina-
tions. Your radiologist may recommend an adjunct US
if you have very dense breasts and a negative mammo-
gram, also taking into account other risk factors. If you
feel a palpable lump, US may be the first-line examina-
tion used, especially before 40 years of age.
Indications for breast US
Definite, possible, and inappropriate indications for breast US
are listed in Tables 1, 2, and 3, respectively. In the following
paragraphs we will enter into the details for those indications
being most clinically relevant or debated.
Screening
In high-risk women who cannot undergo screening with MRI,
US is indicated in very youngwomen under about 30–35 years
of age and as an adjunct to mammography in older women
[32, 33]. Of note, in BRCA mutation carriers, evidence of
higher sensitivity to radiation exposure of the breast tissue
[34] suggests avoiding mammography, at least at young age.
Table 1 Definite indications for breast ultrasound
Palpable lump
Axillary adenopathy
First approach for clinical breast abnormalities under age 40
First approach for clinical breast abnormalities in pregnant
or lactating women
Suspicious abnormalities at mammography or magnetic
resonance imaging (MRI)
Suspicious nipple discharge
Recent nipple inversion
Skin retraction
Breast inflammation
Abnormalities at the surgical scar after breast conserving
surgery or mastectomy
Abnormalities in the presence of breast implants
Screening high-risk women, especially when MRI is not performed
Loco-regional staging of a known breast cancer, when MRI is
not performed
Guidance for percutaneous breast interventions (needle biopsy,
pre-surgical localisation, fluid collection drainage)
Monitoring patients with breast cancer receiving neo-adjuvant
therapy, when MRI is not performed)
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In women at average or intermediate risk with dense
breasts, supplemental screening with either handheld or auto-
mated bilateral breast US can be performed after a negative
mammogram to increase cancer detection, albeit at the price of
a high false positive recall rate. Additionally, invasive cancers
detected by US, which tend to be small and node negative, are
thus more likely to be treated with curative intent [35]. Taking
into consideration that interval cancers are those diagnosed in
the time interval between two scheduled screening examina-
tions, the addition of US screening to mammography in wom-
en with dense breasts has been shown in one study [36] to
reduce the interval cancer rate to a level similar to that ob-
served in women with non-dense breasts screened with mam-
mography only. These results support implementation of re-
search in randomised controlled trials on additional US in
women with increased breast tissue density. A systematic re-
view published in 2009 [37] reported that supplemental breast
US screening after negative mammography in women with
American College of Radiology (ACR) density 2–4 allowed
a cancer detection rate of 0.32% (mean size 9.9 mm, negative
nodal status), most cancers being detected in women with
ACR density 3 or 4, with biopsy rates from 2.3% to 4.7%
and a PPV from 8.4% to 13.7%, about one third of the PPV
of mammography.
A recent study showed that the ability of US to detect breast
cancers is comparable to that of mammography in asymptom-
atic women with heterogeneously or extremely dense breast
tissue in at least one quadrant and at least one other risk factor
for breast cancer, even though with a trade-off in terms of a
higher rate of false positive recall and biopsy [38]. Disease-free
and overall survival after detection with screening US were
reported to be comparable with those after mammography in
Chinese women [39]. However, the performance of breast US
in a population with a high prevalence of women with small
and dense breasts cannot be translated to the European or
American population. In summary, adjunctive US screening
can detect biologically important cancers, but there is not suf-
ficient evidence in favour of adopting adjunctive US screening
as a general policy [40]. Well-designed large studies with suf-
ficient follow-up are needed.
When considering US screening, one relevant issue is the
risk of false positive findings. Only fewer than one of ten
biopsies prompted by US turns out to be malignant [41].
The high rate of biopsy poses major problems when applying
this method to a population every one or two years: every
womanmight undergo one or two biopsies during her lifetime.
Moreover, US screening is more time consuming than mam-
mography for both the patient and the radiologist. Whereas
breast US screening takes about 20 min to perform, the acqui-
sition of a screening mammogram by a radiographer is com-
pleted in 5 min and it takes approximately 1–2 min to be
interpreted by the radiologist [42]. Automated whole breast
US allows the acquisition of imaging data of both breasts in
about 15–20 min by a technician and must be read by a radi-
ologist at a later time in about 5–9 min [11]. This approach
implies a relatively high false positive rate [23, 43]. Research
to define the role of automated breast US is still needed.
US screening instead of screening mammography is not
recommended in women at average risk of breast cancer due
to the combination of a possible reduced sensitivity (especial-
ly in fatty breasts) and a possible increase of false negatives,
i.e. cancers missed.
Diagnostic assessment
In patients with symptoms or signs suspicious for breast can-
cer, which typically comprise palpable lumps (but also, nipple
inversion, localised skin retraction or other modifications, se-
rous or bloody nipple discharge), US is an established tool
complementing clinical examination and mammography at
all ages. It is the method of choice for assessing breast lumps
in young women. US can also reveal the origin of the symp-
toms in patients with painful cysts [44]. When patients present
with unilateral, localised, non-cyclic breast pain, the chance of
malignancy is as low as 1% [45]. In pregnant or lactating
women with a palpable lump, focal breast pain, or nipple
discharge, US is also the initial modality of choice for identi-
fyingmost benign andmalignant masses [25]. However, when
needed, using adequate shielding, mammography can be sup-
plemented even during pregnancy and injury to the unborn
baby is not expected beyond week 16.
Patients presenting with diffuse breast pain, usually in as-
sociation with the premenstrual phase, are often evaluated and
treated only on a clinical basis.
Table 2 Possible indications for breast ultrasound
Supplemental screening after mammography for women aged 40–74
with dense breasts
Surveillance of women with previous mammographically occult breast
cancer
Palpable lump felt by the woman with normal clinical examination
Focal new breast pain unrelated to the menstrual cycle
Intraoperative US lesion identification and US of specimens
Table 3 Inappropriate indications for breast ultrasound
Screening for breast cancer in average-risk women under age 40
Screening for breast cancer as a stand-alone alternative to mammography
in average-risk women with ≥40 years of age
Follow-up in women with previous history of breast cancer as an
alternative to mammography
Diffuse bilateral premenstrual breast pain
Screening of breast implant integrity in asymptomatic women
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Assessment of lesions detected by mammography
Targeted US plays a complementary role when a mass or an
asymmetry is seen on a mammogram. It may help in differ-
entiating cystic from solid lesions and excluding or identi-
fying a solid mass underlying an asymmetry. In the presence
of clustered calcifications, particularly clusters larger than
10 mm, US can depict associated masses, ductal change,
or intracystic lesions, cysts and microcysts that may be cru-
cial for diagnosis [25, 46].
Note E:Mammography is clearly superior to US in iden-
tifying and characterising calcifications. However, in the
presence of calcifications on mammography, targeted US
is recommended to reveal possible underlying masses.
Assessment of lesions detected by MRI
Breast MRI is the most sensitive tool for diagnosing breast
cancer [33], in particular when mammographic calcifica-
tions are absent [47, 48]. Of note, a variable number of
lesions detected on MRI are not identifiable on mammog-
raphy and US and performing an MRI-guided biopsy for
each of these lesions may be disadvantageous, because
most of them are benign. US plays an essential role in
the work-up of MRI-detected lesions. In fact, even when
an US performed before MRI did not reveal abnormalities,
a second-look targeted US after MRI may reveal the lesion:
from 46% to 71% of MRI-detected lesions can be identi-
fied by targeted US [25], more often for larger than for
smaller lesions [49]. Identifying an MRI-detected lesion
on US allows for planning a US-guided biopsy, which is
more comfortable for the patient, cheaper, and less time
consuming than an MRI-guided biopsy. Notably, to visual-
ise MRI abnormalities on US, specific experience and skill
are required, especially for the crucial issue of an accurate
MRI-US spatial correlation. Differences in patient position-
ing during the two examinations may lead to difficulties in
correlation and to incorrect false negative biopsies.
Conversely, a lesion not identified with a pre-MRI US
and identified with a post-MRI (second look) US does
not mean that the first examination was not correctly per-
formed: small lesions can go unnoticed at US when their
location is unknown before MRI but become visible when
MRI indicates their exact localisation. Marker placement
and follow-up imaging after US-guided biopsy (see below)
should be performed [25, 50, 51]. In the case of US-guided
biopsy of an MRI-detected lesions giving a pathological
result not fitting with the MRI finding, MRI could be re-
peated. If an MRI-detected suspicious lesion is not
recognised on US, an MRI-guided biopsy is mandatory
[52].
US-guided percutaneous interventions
Most breast cancers are detected by screening mammography
or because of clinical symptoms. The standard workflow to
assess suspicious lesions is based on mammography, US, and
–when necessary – image-guided needle biopsy. Criteria were
developed for decision making about biopsy of US-detected
masses [21, 53, 54]. When a suspicious lesion is identifiable
on US, US is the preferred image guidance technique for per-
cutaneous needle biopsy [55, 56]. In fact, the procedure is fast,
has low costs, allows for the use of smaller needles, is only
minimally uncomfortable for the patient and does not expose
the patient to radiation. US-guided breast biopsies offer great
advantages over mammography orMRI guidancemethods for
needle biopsy. US-guided interventions can be requested not
only by radiologists but also by referring physicians to
established histopathologic diagnosis and allow treatment
planning. Open surgical diagnostic biopsies are performed
only in a few particular cases, either when image-guided bi-
opsy is not possible or due to patient’s preference.
Independent of whether a mass is palpable or not, US
guidance allows the operator to follow the procedure in real
time and to verify the needle position for improving the
overall accuracy. The patient position during biopsy is quite
similar to the US examination. Breast compression is not
required. The skin is disinfected and local anaesthesia is
injected. A small incision of the skin is sometimes made
at the entry site for an easier needle passage. The current
good practice is the use of a 14-gauge or larger needle
(which means using needles identified with smaller gauge
numbers) to obtain three to six samples [50, 51]. Markers
visible at various imaging modalities may be positioned at
the biopsy site under US guidance, especially when there is
a chance of masking or the disappearance of the biopsied
lesion due to bleeding or very small size. This final step
allows the evaluation of the concordance of the biopsy
position as compared with other imaging modalities and,
in case of neo-adjuvant therapy (i.e. a systemic medical
treatment adopted in the case of large tumours to be re-
duced before surgery), to have the tumour position marked
also in the case of complete response to therapy.
US-guided needle biopsy is a minimally invasive and safe
technique for obtaining histologic diagnosis of a breast mass.
The risk of complications such as infections and large
haematomas (sometimes with pseudoaneurysms) is very
low, approximately one every 1000 procedures [50, 51].
Further, pre-surgical localisation of non-palpable lesions can
be similarly easily performed under US guidance in order to
indicate the site or the disease extent to the surgeon.
Mammography- and MRI-guided procedures (both biopsies
and localisations) are reserved for those lesions not visible on
US, as those procedures are more uncomfortable and more
time consuming than under US guidance.
Insights Imaging (2018) 9:449–461 455
During US-guided interventions, usually a nurse or a tech-
nologist assists the radiologist. More detailed information will
be provided in a specific article dedicated to image-guided
breast interventions.
Loco-regional staging
In women with a suspected breast cancer, detected with US or
with other modalities, the whole breast harbouring the suspi-
cious lesion, the ipsilateral axilla, and the contralateral breast
can be examined with US. In fact, US has proven to be very
valuable for assessing the size of invasive cancers, detecting
other cancer foci in the affected breast, and identifying cancers
in the contralateral breast [57–59]. Occult ipsilateral or con-
tralateral cancers are more frequently found with US if the
known cancer is palpable or larger than 2 cm, especially in
the context of dense breasts [58].
However, the most accurate method for detecting ad-
ditional ipsilateral and contralateral cancers in women
with a newly diagnosed breast cancer is breast MRI,
even though its routine preoperative use is still contro-
versial [3]. At any rate, the additional findings of MRI
can be considered for changing therapy planning only if
they are pathologically verified to be malignant through
a percutaneous biopsy. If an additional lesion seen on
MRI is also visible on targeted (so-called second look,
as mentioned above) US, the biopsy should be per-
formed under US guidance [52]. If an additional lesion
cannot be identified at targeted second-look US, the
radiologist, together with a multidisciplinary team, will
decide the next step, such as an MRI-guided biopsy or
follow-up [3].
When an invasive cancer is newly diagnosed, the status of
axillary lymph nodes is important for treatment planning, in
particular for decision making about axillary treatment (i.e.,
surgical removal or radiation therapy of axillary lymph-
nodes), and prognosis. Lymph nodes suspected of harbouring
metastases can be revealed by US also in the absence of pal-
pable axillary findings. In that case, US-guided percutaneous
sampling concludes the diagnostic work-up, using fine needle
aspiration or larger core needles [60].
Evaluation of the effect of neoadjuvant therapy
Locally advanced cancers are defined as tumours that are
larger than 5 cm in size in the absence of metastases to
other organs or tumours of any size with direct extension
to the chest wall or to the skin as well as with clinically
fixed or matted axillary lymph-nodes, or any of infra-
clavicular, supraclavicular, or internal mammary lymph-
node involvement regardless of tumour stage [61]. These
tumours are often treated with systemic treatment using
different drugs before surgery, an approach referred as
neo-adjuvant therapy. The aim is to reduce the tumour
bulk, allowing for conservative surgery and preventing
the spread to distant organs. Of note, the tumour in the
breast and axillary involvement may respond differently.
In recent years, indications for neoadjuvant therapy also
have been extended to non-locally-advanced breast can-
cers, such as small (less than 2 cm in diameter) triple-
negative cancers (those which are oestrogen-receptor,
progesterone receptor, and human epidermal growth
factor receptor 2 negative) [62].
Breast US has been shown to be a useful tool for
early prediction of pathologic response to this kind of
treatment [63] and may potentially aid the optimisation
of therapy in case the of poor response, allowing for a
prompt regimen change. However, it has to be noted that
in this setting breast MRI has been shown to offer the
best performance [64–67].
Patients with breast implants
Breast US is usually the first line examination performed in
women with implants to investigate breast implant complica-
tions that may present with pain, lumps, or asymmetries. It can
be used to detect alterations of the implant structure, typically
subdivided into intracapsular ruptures (when the implant en-
velope is broken but the silicon remains inside the capsule)
and extracapsular ruptures (when the silicone leaks out of the
broken capsule) [68]. Of note, the fibrotic capsule around the
implant develops through a natural foreign body reaction of
the breast tissues to the implant.
Considering breast implant integrity, US is a very specific,
although not very sensitive, method: if an implant rupture is
suspected on US, the probability of a true rupture is high;
conversely, if no rupture is visible on US, a rupture (mostly
intra-capsular) is still possible. In addition, US is useful in
diagnosing other implant complication such as infection,
seroma, or granuloma. MRI is the usual second step after
US in this setting, especially for detecting intracapsular rup-
tures unnoticed with US [33, 69].
There are no contraindications to performing US-guided
interventions (biopsy, preoperative localisation) in women
with breast implants [17].
Note F. If you have breast implants, for either aesthetic
reasons or from oncoplastic surgery, and a breast exam-
ination is planned (including US), please give the radiol-
ogist a complete information about the type of your
breast implant, if this information is available to you.
There are many implant types (e.g., double or single lu-
men, silicone-only or silicone and saline solution, etc.)
and the diagnostic performance is increased when the
radiologist is aware of the type of implant you have.
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Intraoperative US lesion identification and US
of specimens
Although it is not commonly used in clinical practice, some
experiences have been reported about the use of US for peri-
operative lesion identification in breast conserving surgery,
with the aim of better margin management [70, 71].
Ultrasound of the surgical specimen may be used for evaluat-
ing the presence of the lesion and resection margin status
[71–74], especially in the case of non-palpable lesions not
associated with calcifications or not identifiable at
mammography.
The breast US report
Breast US should be performed by a dedicated breast radiol-
ogist who is also skilled in mammography and image-guided
interventions. The report should start with a premise contain-
ing relevant clinical information and the indication to the
examination. A short statement on the technique can be useful
in documenting the use of a state-of-the-art equipment. In the
descriptive section, the findings should be detailed, including
abnormalities in the breasts and, when explored, the axillae.
The descriptive section should include: laterality, the location
of the finding(s) using the subdivision into four quadrants
(upper external, lower external, lower internal, upper internal)
plus the retro-areolar region and/or the clockwise position and
distance from the nipple; the sonographic features; the size
using the maximal diameter; the possible association with
findings at clinical examination or on other imaging modali-
ties. Concordance or difference in comparisons with previous
breast US or other imaging examinations must be reported.
The report should end with a concise conclusion, including a
stardardised assessment category and management recom-
mendations. Relevant verbal discussions between the
interpreting physician and the referring clinician or the patient
can be documented (e.g., in the original report or in an adden-
dum to the report).
In most countries, a structured reporting and classification
system is adopted for describing breast US findings and guid-
ing management. In some European countries, especially in
the United Kingdom, a five-level scale from U1 to U5 is used,
where U stands for US. U1 means normal (no abnormalities),
U2 benign abnormal findings, U3 indeterminate (equivocal)/
probably benign findings, U4 findings suspicious of
malignancy, U5, findings highly suspicious of malignancy
[75]. The most commonly applied system is the ACR Breast
Imaging Reporting And Data System (BI-RADS) [21]. BI-
RADS 1 means normal (no abnormalities), BI-RADS 2 be-
nign abnormal findings, BI-RADS 3 probably benign findings
(for which a short-interval – typically 6-month – follow-up is
recommended), BI-RADS 4 suspicious findings for which
needle biopsy is recommended, BI-RADS 5 findings highly
suggestive for malignancy for which needle biopsy is recom-
mended, BI-RADS 6 known biopsy-proven malignancy (re-
served for US examinations performed made for cancer stag-
ing or monitoring of neo-adjuvant therapy). Finally, this sys-
tem also includes a BI-RADS 0 category, which is used for
incomplete/inconclusive tests requiring additional imaging
evaluation. Note that both the U4/BI-RADS 4 and U5/BI-
RADS 5 diagnostic categories require tissue sampling through
biopsy. In contrast to the U3 category (which includes cases
with a relatively higher probability of cancer), the BI-RADS 3
category implies a low cancer risk (lower than 2%) and re-
quires short term (usually 6 months) follow-up but may also
be biopsied if the patient requests it or when follow-up is
deemed difficult [21].
Note G. Even though the use of stardardised assessment
categories facilitates the understanding of the report, do
not hesitate to discuss unclear issues of your US exami-
nation with your breast radiologist. Do this in particular
in the case of U3 or BI-RADS 3, if you are wondering
about the need to undergo a needle biopsy or you are
thinking of postponing the needle biopsy, as well as in
the case of U4/BI-RADS 4 or U5/BI-RADS 5 and when
further imaging work-up is suggested (e.g., digital breast
tomosynthesis, MRI).
Conclusions
Ultrasound is a safe and widely available method for breast
imaging. It is the method of choice when assessing young
women (under age 40) with a palpable lump and a comple-
mentary method after mammography in older women with a
palpable lump. Breast cancer screening with breast US alone
is discouraged, while supplemental screening with USmay be
an option to be considered for womenwith dense breasts, even
though associated with a high false positive rate. When a
tissue diagnosis is needed for a suspicious lesion, US-guided
biopsy should be preferred if the lesion is clearly identified
with this method.
Frequently asked questions (FAQs)
1. Is breast US a harmless investigation?
Yes. To the best of our knowledge, there are no reported
harms related to the delivery of US to the adult human body at
the level of energy applied in diagnostic medical use [4, 76].
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2. Can breast US be performed instead of mammogra-
phy for breast cancer screening in the general female
population, as it spares radiation?
No. US has not been shown to reduce mortality from breast
cancer when used a stand-alone approach in the general fe-
male population, and it causes far more biopsies and short-
term follow-up examinations than mammography.
3. After a breast US examination, does the woman also
need mammography?
The answer depends on the setting. As mentioned above,
US is not accurate enough to be considered a stand-alone
screening method in the general female population. It can be
considered as an adjunct to mammography in asymptomatic
women for certain specific categories (e.g., women with dense
breasts) and may be the first-choice, however often not the
only method needed, to correctly assess a woman with palpa-
ble lump, regardless of age, breast density, or breast cancer
risk. Ask your radiologist to find out if you need a mammo-
gram after a US or a US after a mammogram. She/he will be
able to answer the question and to explain the reasons for yes
or no.
4. Can women consider breast US being free from any
potential negative consequences?
No. If breast US is not indicated and is performed, for
example for screening in very young women at average
risk for breast cancer, there is a non-negligible chance of
false positive findings which could require unnecessary
further work-up including needle biopsy or additional
imaging procedures, causing anxiety to the woman and
costs to the health care system. In addition, women
should not forget that if US is used as a stand-alone
screening tool instead of mammography, cancers could
be missed, especially in fatty breasts.
5. After receiving the result of a breast handheld US, can
women try to get a reliable second opinion on the test?
This possibility is limited by important technical reasons. If
the original examiner missed a lesion, no documentation ex-
ists of this. Thus, in the vast majority of cases, the only way to
get a real second opinion is for the breast US examination to
be repeated by another examiner. This underlines the impor-
tance of selecting quality-assured/certified breast imaging
centres for the original breast US examination. Notably, this
is not true for mammography, which can be read by a second
radiologist without it being necessary to repeat the test, (with
only few exceptions due to technical deficits of the original
mammogram).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Sardanelli F, Helbich TH (2012) Mammography: EUSOBI recom-
mendations for women's information. Insights Imaging 3:7–10
2. Sardanelli F, Fallenberg EM,Clauser P et al (2017)Mammography:
an update of the EUSOBI recommendations on information for
women. Insights Imaging 8:11–18
3. Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI:
EUSOBI recommendations for women’s information. Eur Radiol
25:3669–3678
4. Ziskin MC (1993) Fundamental physics of ultrasound and its prop-
agation in tissue. Radiographics 13:705–709
5. Venta LA, Dudiak CM, Salomon CG, Flisak ME (1994)
Sonographic evaluation of the breast. Radiographics 14:29–50
6. Britton P, Warwick J, Wallis MG et al (2012) Measuring the accu-
racy of diagnostic imaging in symptomatic breast patients: team and
individual performance. Br J Radiol 85:415–422
7. The American College of Radiology (2016) ACR–AAPM
Technical standard for diagnostic medical physics performance
monitoring of real time ultrasound equipment. http://www.acr.org.
Accessed 08 Sep 2017
8. Wilson AR, Marotti L, Bianchi S et al (2013) The requirements of a
specialist breast centre. Eur J Cancer 49:3579–3587
9. European Society of Radiology (ESR) (2014) Renewal of radiolog-
ical equipment. Insights Imaging 5:543–546
10. Vourtsis A, Kachulis A (2018) The performance of 3DABUS versus
HHUS in the visualisation and BI-RADS characterisation of breast
lesions in a large cohort of 1,886 women. Eur Radiol 28:592–601
11. Skaane P, Gullien R, Eben EB, Sandhaug M, Schulz-Wendtland R,
Stoeblen F (2015) Interpretation of automated breast ultrasound
(ABUS) with and without knowledge of mammography: a reader
performance study. Acta Radiol 56:404–412
12. Perry N, Broeders M, deWolf C, Törnberg S, Holland R, von Karsa
L (2008) European guidelines for quality assurance in breast cancer
screening and diagnosis. Fourth edition–summary document. Ann
Oncol 19:614–622
13. Sung JS (2014) High-quality breast ultrasonography. Radiol Clin N
Am 52:519–526
14. Lee SH, Yi A, Jang MJ, Chang JM, Cho N, Moon WK (2017)
Supplemental screening breast US in women with negative mam-
mographic findings: effect of routine axillary scanning. Radiology
30:171218. https://doi.org/10.1148/radiol.2017171218
15. del Cura JL, Elizagaray E, Zabala R, Legórburu A, Grande D
(2005) The use of unenhanced Doppler sonography in the evalua-
tion of solid breast lesions. AJR Am J Roentgenol 184:1788–1794
16. Mehta TS, Raza S, Baum JK (2000) Use of Doppler ultrasound in
the evaluation of breast carcinoma. Semin Ultrasound CT MR 21:
297–307
17. Mahoney MC, Newell MS (2013) Breast intervention: how I do it.
Radiology 268:12–24
18. Raza S, Odulate A, Ong EM, Chikarmane S, Harston CW (2010)
Using real-time tissue elastography for breast lesion evaluation: our
initial experience. J Ultrasound Med 29:551–563
19. Lee SH, Chang JM, Kim WH et al (2014) Added value of shear-
wave elastography for evaluation of breast masses detected with
screening US imaging. Radiology 273:61–69
458 Insights Imaging (2018) 9:449–461
20. Berg W, Cosgrove D, Doré C et al (2012) Shear-wave elastography
improves the specificity of breast US: the BE1 multinational study
of 939 masses. Radiology 262:435–449
21. Mendelson EB, Bohm-Velez M, Berg WA et al (2013) ACR BI-
RADS® ultrasound. ACR BI-RADS® atlas, breast imaging
reporting and data system. American College of Radiology,
Reston, VA
22. Meng Z, Chen C, Zhu Yet al (2015) Diagnostic performance of the
automated breast volume scanner: a systematic review of inter-rater
reliability/agreement and meta-analysis of diagnostic accuracy for
differentiating benign and malignant breast lesions. Eur Radiol 25:
3638–3647
23. Brem RF, Tabár L, Duffy SW et al (2015) Assessing improvement
in detection of breast cancer with three-dimensional automated
breast US in women with dense breast tissue: the SomoInsight
study. Radiology 274:663–673
24. Wilczek B, Wilczek HE, Rasouliyan L, Leifland K (2016) Adding
3D automated breast ultrasound to mammography screening in
women with heterogeneously and extremely dense breasts: report
from a hospital-based, high-volume, single-center breast cancer
screening program. Eur J Radiol 85:1554–1563
25. Hooley RJ, Scoutt LM, Philpotts LE (2013) Breast ultrasonogra-
phy: state of the art. Radiology 268:642–659
26. Irwig L, Houssami N, van Vliet C (2004) New technologies in
screening for breast cancer: a systematic review of their accuracy.
Br J Cancer 90:2118–2122
27. Houssami N, Lord SJ, Ciatto S (2009) Breast cancer screening:
emerging role of new imaging techniques as adjuncts to mammog-
raphy. Med J Aust 190:493–497
28. Tagliafico AS, Calabrese M, Mariscotti G et al (2016) Adjunct
screening with tomosynthesis or ultrasound in women with
mammography-negative dense breasts: interim report of a prospec-
tive comparative trial. J Clin Oncol 34:1882–1888
29. Melnikow J, Fenton JJ, Whitlock EP et al (2016) Supplemental
screening for breast cancer in women with dense breasts: a system-
atic review for the U.S. Preventive Service Task Force
[Internet].Rockville (MD): Agency for Healthcare Research and
Quality (United States). Report No.: 14–05201-EF-3. U.S.
Preventive Services Task Force Evidence Syntheses, formerly
Systematic Evidence Reviews
30. Mann RM, Hoogeveen YL, Blickman JG, Boetes C (2008) MRI
compared to conventional diagnostic work-up in the detection and
evaluation of invasive lobular carcinoma of the breast: a review of
existing literature. Breast Cancer Res Treat 107:1–14
31. Kim MY, Kim HS, Choi N, Yang JH, Yoo YB, Park KS (2015)
Screening mammography-detected ductal carcinoma in situ: mam-
mographic features based on breast cancer subtypes. Clin Imaging
39:983–986
32. BergWA, Blume JD, Cormack JB et al (2008) Combined screening
with ultrasound and mammography vs mammography alone in
women at elevated risk of breast cancer. JAMA 299:2151–2163
33. Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance
imaging of the breast: recommendations from the EUSOMAwork-
ing group. Eur J Cancer 46:1296–1316
34. Colin C, Foray N, Di Leo G, Sardanelli F (2017) Radiation induced
breast cancer risk in BRCA mutation carriers from low-dose radio-
logical exposures: a systematic review. Radioprotection. https://doi.
org/10.1051/radiopro/2017034
35. Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD (2014)
Screening ultrasound as an adjunct to mammography in women
with mammographically dense breasts. Am J Obstet Gynecol
212:9–17
36. Corsetti V, Houssami N, Ghirardi M et al (2011) Evidence of the
effect of adjunct ultrasound screening in women with
mammography-negative dense breasts: interval breast cancers at 1
year follow-up. Eur J Cancer 47:1021–1026
37. Nothacker M, Duda V, Hahn M et al (2009) Early detection of
breast cancer: benefits and risks of supplemental breast ultrasound
in asymptomatic women with mammographically dense breast tis-
sue. A systematic review. BMC Cancer 9:335
38. Berg WA, Bandos AI, Mendelson EB, Lehrer D, Jong RA, Pisano
ED (2015) Ultrasound as the primary screening test for breast can-
cer: analysis FromACRIN 6666. J Natl Cancer Inst 108. https://doi.
org/10.1093/jnci/djv367
39. Pan B, Yao R, Zhu QL et al (2016) Clinicopathological character-
istics and long-term prognosis of screening detected non-palpable
breast cancer by ultrasound in hospital-based Chinese population
(2001-2014). Oncotarget 7:76840–76851
40. Sprague BL, Stout NK, Schechter C et al (2015) Benefits, harms,
and cost-effectiveness of supplemental ultrasonography screening
for women with dense breasts. Ann Intern Med 162:157–166
41. Chang JM, Koo HR, Moon WK (2015) Radiologist-performed
hand-held ultrasound screening at average risk of breast cancer: re-
sults from a single health screening center. Acta Radiol 56:652–658
42. Bernardi D, Ciatto S, Pellegrini M et al (2012) Application of breast
tomosynthesis in screening: incremental effect on mammography
acquisition and reading time. Br J Radiol. https://doi.org/10.1259/
bjr/19385909
43. Arleo EK, Saleh M, Ionescu D, Drotman M, Min RJ, Hentel K
(2014) Recall rate of screening ultrasound with automated breast
volumetric scanning (ABVS) in women with dense breasts: a first
quarter experience. Clin Imaging 38:439–444
44. Cid JA, Rampaul RS, Ellis IO et al (2004) Woman feels breast
lump-surgeon cannot: the role of ultrasound in arbitration. Eur J
Cancer 40:2053–2055
45. Leddy R, Irshad A, Zerwas E et al (2013) Role of breast ultrasound
and mammography in evaluating patients presenting with focal
breast pain in the absence of a palpable lump. Breast J 19:582–589
46. Moon WK, Im JG, Koh YH, Noh DY, Park IA (2000) US of
mammographically detected clustered microcalcifications.
Radiology 217:849–854
47. Bennani-Baiti B, Bennani-Baiti N, Baltzer PA (2016) Diagnostic
performance of breast magnetic resonance imaging in non-calcified
equivocal breast findings: results from a systematic review and
meta-analysis. PLoS One 11:e0160346
48. Bennani-Baiti B, Baltzer PA (2017) MR imaging for diagnosis of
malignancy in mammographic microcalcifications: a systematic re-
view and meta-analysis. Radiology 283:692–701
49. Meissnitzer M, Dershaw DD, Lee CH, Morris EA (2009) Targeted
ultrasound of the breast in women with abnormal MRI findings for
whom biopsy has been recommended. AJR Am J Roentgenol 193:
1025–1029
50. Liberman L, Feng TL, Dershaw DD, Morris EA, Abramson AF
(1998) US-guided core breast biopsy: use and cost-effectiveness.
Radiology 208:717–723
51. Apesteguía L, Pina LJ (2011) Ultrasound-guided core-needle biop-
sy of breast lesions. Insights Imaging 2:493–500
52. Spick C, Baltzer PA (2014) Diagnostic utility of second-look US for
breast lesions identified at MR imaging: systematic review and
meta-analysis. Radiology 273:401–409
53. Graf O, Helbich TH, Fuchsjaeger MH et al (2004) Follow-up of
palpable circumscribed noncalcified solid breast masses at mam-
mography and US: can biopsy be averted? Radiology 233:850–856
54. Graf O, Helbich TH, Hopf G, Graf C, Sickles EA (2007) Probably
benign breast masses at US: is follow-up an acceptable alternative
to biopsy? Radiology 244:87–93
55. Schueller G, Schueller-Weidekamm C, Helbich TH (2008)
Accuracy of ultrasound-guided, large-core needle breast biopsy.
Eur Radiol 18:1761–1773
56. Schueller G, Jaromi S, Ponhold L et al (2008) US-guided 14-gauge
core-needle breast biopsy: results of a validation study in 1352
cases. Radiology 248:406–413
Insights Imaging (2018) 9:449–461 459
57. Berg WA, Gilbreath PL (2000) Multicentric and multifocal cancer:
whole-breast US in preoperative evaluation. Radiology 214:59–66
58. Moon WK, Noh DY, Im JG (2002) Multifocal, multicentric, and
contralateral breast cancers: bilateral whole-breast US in the preop-
erative evaluation of patients. Radiology 224:569–576
59. Kim AH, Kim MJ, Kim EK, Park BW, Moon HJ (2014) Positive
predictive value of additional synchronous breast lesions in whole
breast ultrasonography at the diagnosis of breast cancer: clinical and
imaging factors. Ultrasonography 33:170–177
60. Ganott MA, ZuleyML, Abrams GS et al (2014) Ultrasound-guided
core biopsy versus fine needle aspiration for evaluation of axillary
lymphadenopathy in patients with breast cancer. ISRN Oncol:
703160
61. Garg PK, Prakash G (2015) Current definition of locally advanced
breast cancer. Curr Oncol. https://doi.org/10.3747/co.22.2697
62. Liedtke C, RodyA (2017) Neoadjuvant therapy for patients with triple
negative breast cancer (TNBC). Rev Recent Clin Trials 12:73–80
63. Marinovich ML, Houssami N, Macaskill P, von Minckwitz G,
Blohmer JU, Irwig L (2015) Accuracy of ultrasound for predicting
pathologic response during neoadjuvant therapy for breast cancer.
Int J Cancer 136:2730–2737
64. Marinovich ML, Sardanelli F, Ciatto S et al (2012) Early prediction
of pathologic response to neoadjuvant therapy in breast cancer:
systematic review of the accuracy of MRI. Breast 21:669–677
65. Marinovich ML, Macaskill P, Irwig L et al (2013) Meta-analysis of
agreement between MRI and pathologic breast tumour size after
neoadjuvant chemotherapy. Br J Cancer 109:1528–1536
66. Marinovich ML, Houssami N, Macaskill P et al (2013) Meta-
analysis of magnetic resonance imaging in detecting residual breast
cancer after neoadjuvant therapy. J Natl Cancer Inst 105:321–333
67. Marinovich ML, Macaskill P, Irwig L et al (2015) Agreement be-
tween MRI and pathologic breast tumor size after neoadjuvant che-
motherapy, and comparison with alternative tests: individual patient
data meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-
015-1664-4
68. Seiler SJ, Sharma PB, Hayes JC et al (2017) Multimodality
imaging-based evaluation of single-lumen silicone breast implants
for rupture. Radiographics 37:366–382
69. Hold PM, Alam S, Pilbrow WJ et al (2012) How should we inves-
tigate breast implant rupture? Breast J 18:253–256
70. Gray RJ, Pockaj BA, Garvey E, Blair S (2018) Intraoperative mar-
gin management in breast conserving surgery: a systematic review
of the literature. Ann Surg Oncol 25:18–27
71. Ramos M, Díaz JC, Ramos T et al (2013) Ultrasound-guided exci-
sion combined with intraoperative assessment of gross macroscopic
margins decreases the rate of reoperations for non-palpable invasive
breast cancer. Breast 22:520–524
72. Naz S, Hafeez S, Hussain Z, Hilal K (2017) Negative predictive
value of ultrasound in predicting tumor-free margins in specimen
sonography. J Coll Physicians Surg Pak 27:747–750
73. Moschetta M, Telegrafo M, Introna T et al (2015) Role of specimen
US for predicting resection margin status in breast conserving ther-
apy. G Chir 36:201–204
74. Londero V, Zuiani C, PanozzoM, Linda A, Girometti R, Bazzocchi
M (2010) Surgical specimen ultrasound: is it able to predict the
status of resection margins after breast-conserving surgery? Breast
19:532–537
75. Maxwell AJ, Ridley NT, Rubin G et al (2009) Royal college of
radiologists breast group imaging classification. Clin Radiol 64:
624–627
76. Barnett SB, Ter Haar GR, ZiskinMC, Rott HD, Duck FA,Maeda K
(2000) International recommendations and guidelines for the safe
use of diagnostic ultrasound in medicine. Ultrasound Med Biol 26:
355–366
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
460 Insights Imaging (2018) 9:449–461
Affiliations
Andrew Evans1 &RubinaM. Trimboli2 &Alexandra Athanasiou3 &Corinne Balleyguier4 &Pascal A. Baltzer5 &Ulrich Bick6 &
Julia Camps Herrero7 & Paola Clauser5 & Catherine Colin8 & Eleanor Cornford9 & Eva M. Fallenberg6 &
Michael H. Fuchsjaeger10 & Fiona J. Gilbert11 & Thomas H. Helbich5 & Karen Kinkel12 & Sylvia H. Heywang-Köbrunner13 &
Christiane K. Kuhl14 & Ritse M. Mann15 & Laura Martincich16 & Pietro Panizza17 & Federica Pediconi18 &
Ruud M. Pijnappel19 & Katja Pinker5,20 & Sophia Zackrisson21 & Gabor Forrai22 & Francesco Sardanelli23,24
1 Dundee Cancer Centre, Clinical Research Centre, Ninewells
Hospital and Medical School, TomMcDonald Avenue, Dundee, UK
2 PhD Course in Integrative Biomedical Research, Department of
Biomedical Science for Health, Università degli Studi di Milano, Via
Mangiagalli, 31, 20133 Milan, Italy
3 Breast Imaging Department, MITERA Hospital, 6, Erithrou Stavrou
Str. 151 23 Marousi, Athens, Greece
4 Department of Radiology, Gustave-Roussy Cancer Campus, 114
Rue Edouard Vaillant, 94800 Villejuif, France
5 Department of Biomedical Imaging and Image-guided Therapy,
Division of Molecular and Gender Imaging, Medical University of
Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria
6 Clinic of Radiology, Charité Universitätsmedizin Berlin,
10117 Berlin, Germany
7 Department of Radiology, University Hospital of La Ribera,
Carretera de Corbera, Km 1, 46600 Alzira, Valencia, Spain
8 Radiology Unit, Hospices Civils de Lyon, Centre Hospitalo-
Universitaire FemmeMère Enfant, 59 Boulevard Pinel, 69 677 Bron
Cedex, France
9 Thirlestaine Breast Centre, Cheltenham General Hospital,
Thirlestaine Road, Cheltenham GL53 7AP, UK
10 Division of General Radiology, Department of Radiology, Medical
University Graz, Auenbruggerplatz 9, 8036 Graz, Austria
11 Department of Radiology, University of Cambridge, Cambridge
Biomedical Campus, Hills road, Cambridge CB2 0QQ, UK
12 Institut de Radiologie, Clinique des Grangettes, Chemin des
Grangettes 7, 1224 Chêne-Bougeries, Genève, Switzerland
13 Referenzzentrum Mammographie München and FFB gGmbH
München, Sonnenstraße 29, 80331 Munich, Germany
14 University Hospital of Aachen, Rheinisch-Westfälische Technische
Hochschule, Pauwelsstraße 30, 52074 Aachen, Germany
15 Department of Radiology, Radboud University Nijmegen Medical
Centre, Geert Grooteplein Zuid 10, 6525
GA Nijmegen, The Netherlands
16 Unità Operativa Radiodiagnostica, Candiolo Cancer Institute - FPO,
IRCCS, Str. Prov. 142, km 3.95, 10060 Candiolo, Turin, Italy
17 Breast Imaging Unit, Scientific Institute (IRCCS) Ospedale San
Raffaele, Via Olgettina, 60, 20132 Milan, Italy
18 Department of Radiological, Oncological and Pathological
Sciences, Sapienza University, Viale Regina Elena, 324,
00161 Rome, Italy
19 Department of Imaging, University Medical Centre Utrecht,
Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
20 Department of Radiology, Breast Imaging Service, Memorial Sloan
Kettering Cancer Center, 300 E 66th Street, New York, NY 10065,
USA
21 Diagnostic Radiology, Department of Translational Medicine,
Faculty of Medicine, Lund University, Skåne University Hospital
Malmö, SE-205 02 Malmö, Sweden
22 Department of Radiology, Duna Medical Center,
Budapest, Hungary
23 Department of Biomedical Sciences for Health, Università degli
Studi di Milano, Via Morandi 30, 20097 San Donato
Milanese, Milan, Italy
24 Unit of Radiology, IRCCS Policlinico San Donato, ViaMorandi 30,
20097 San Donato Milanese, Milan, Italy
Insights Imaging (2018) 9:449–461 461
